<DOC>
	<DOCNO>NCT00002790</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may able replace immune cell destroy chemotherapy use kill tumor cell . Sometimes transplanted cell make immune response body 's normal tissue . Treatment sirolimus , methotrexate , cyclosporine may prevent happen . PURPOSE : Phase I/II trial study effectiveness sirolimus plus methotrexate cyclosporine prevent graft-versus-host disease patient hematologic malignancy receive bone marrow transplant .</brief_summary>
	<brief_title>Prevention Graft-Versus-Host Disease Patients With Hematologic Malignancies Who Are Receiving Bone Marrow Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose rapamycin safely combined standard methotrexate/cyclosporine prophylaxis graft-versus-host disease ( GVHD ) patient hematologic disorder receive bone marrow transplant relate donor mismatch 1 HLA-A , -B , -DR antigen GVHD direction . OUTLINE : This dose escalation study . Groups 6-12 patient receive escalate dos rapamycin maximum tolerate dose rapamycin give combination methotrexate/cyclosporine determine . All patient receive cyclosporine day prior transplant day 50 post-transplant ; dose taper 130 day . Methotrexate give day 1 , 3 , 6 post-transplant . Rapamycin give every day , day 7-59 . Bone marrow transplantation occur day 0 . Patients may receive concurrent therapy agent could interfere rapamycin metabolism , intravenous lipid , FK506 immunosuppressive agent ( prednisone allow ) , NSAIDs , cytotoxic agent . Patients follow 6 month 2 year , annually . PROJECTED ACCRUAL : 12-36 patient accrue 1-2.5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : Age : 13 Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine great 2.0 mg/dL Cardiovascular : No cardiac disease No clinically significant cardiac abnormality No ischemia No recent injury EKG Other : No intolerance unresponsiveness rapamycin No hypersensitivity macrolide antibiotic , e.g. , erythromycin , azithromycin , clarithromycin No requirement medication may significantly affect rapamycin metabolism , i.e . : Carbamazepine Ketoconazole Primidone Cimetidine Nicardipine Rifampin Diltiazem Phenobarbital Valproic acid Erythromycin Phenytoin Verapamil No uncontrolled systemic infection No pregnant nursing woman Negative pregnancy test require fertile woman Effective contraception require fertile patient 3 month study Able tolerate le 400 mL liquid oral intake PRIOR CONCURRENT THERAPY : At least 1 week since investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>chronic myelogenous leukemia</keyword>
	<keyword>childhood acute myeloid leukemia/other myeloid malignancy</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>